Heres what we do know from the few human reports available, and why they offer limited reassurance: Phase I trial (unpublished): In 2015, a formal Phase I trial on 42 healthy volunteers was initiated to assess BPC-157s safety and pharmacokinetics
TB-500, a fragment of Thymosin Beta-4, works primarily through actin regulation and cell migration enhancement
Schmitt H, Billmeier U, Dieterich W et al (2019) Expansion of IL-23 receptor bearing TNFR2+ T cells is associated with molecular resistance to anti-TNF therapy in Crohns disease
Kyo, Nucleus accumbens-1/GADD45GIP1 axis mediates cisplatin resistance through cellular senescence in ovarian cancer
Do not use if you have a history of cancer, tumorous growth conditions, or genetically linked tumor syndromes